Status:
COMPLETED
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Pituitary Dwarfism
Eligibility:
All Genders
3-13 years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ages 3-15
- Presence of growth failure indicated by height standard deviation score less than equal to -2
- Body mass index greater than or equal to 25th percentile for height age
- IGF concentration less than or equal to 33rd percentile
Exclusion
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00102817
Start Date
May 1 2003
End Date
December 1 2006
Last Update
January 18 2017
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90027
2
Novo Nordisk Investigational Site
San Diego, California, United States, 92093
3
Novo Nordisk Investigational Site
Stanford, California, United States, 94305-5208
4
Novo Nordisk Investigational Site
St. Petersburg, Florida, United States, 33701